

Review Article

Molecular mechanisms underlying gallic acid effects against cardiovascular diseases: An update review

Ghaidafeh Akbari^{1,*}

¹Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran

Article history:

Received: Nov 29, 2018

Received in revised form:

Apr 22, 2019

Accepted: May 18, 2019

Vol. 10, No. 1, Jan-Feb 2020,
11-23.

*** Corresponding Author:**

Tel: +989177428836

Fax: +987432332401

ghaidafehakbari@yahoo.com

Keywords:

Gallic acid

Cardiovascular diseases

Molecular mechanisms

Abstract

Objective: The prevalence of cardiovascular diseases (CVDs) is growing. CVDs are the major cause of mortality and have become one of the most important health challenges in developing countries. Gallic acid (GA) is a natural phytochemical which has been widely used against multiple conditions. The present review was designed to evaluate molecular mechanisms underlying the protective effects of this agent against CVDs.

Materials and Methods: Data discussed in this review were collected from the articles published in databases such as Science Direct, Scopus, PubMed, and Scientific Information Database between 1993 and 2018.

Results: According to the experimental studies, GA has protective actions against CVDs through increasing antioxidant enzymes capacity, inhibition of lipid peroxidation and decreasing serum levels of cardiac marker enzymes, modulation of hemodynamic parameters, recovery of electrocardiogram aberrations, and preservation of histopathological changes.

Conclusion: GA has potential cardioprotective action. Therefore, it has been suggested that this agent can be administered in underlying of CVDS.

Please cite this paper as:

Akbari G. Molecular mechanisms underlying gallic acid effects against cardiovascular diseases: An update review. *Avicenna J Phytomed*, 2020; 10(1): 11-23.

Introduction

Cardiovascular diseases (CVDs) are the first etiology of death all over the world. Different forms of CVDs are atherosclerosis, coronary artery disease, arrhythmia, and heart failure (Kang et al., 2015). Risk factors which contribute to CVDs are either unmodifiable (e.g. family history, race and age) or modifiable (e.g. hypertension, high cholesterol, obesity, type 2 diabetes). Thus, primary prevention of CVDs by determining and treating at-risk individuals remains a major public-health problem (Stone et al., 2014).

Antioxidant enzymes including superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione reductase (GRx) and glutathione-s-transferase (GST) are the major cellular defense against injury (Priscilla and Prince, 2009). In the heart, glutathione (GSH) is very important because it can remove organic and inorganic peroxide (Kaul et al., 1993).

It was reported that administration of fresh fruits, vegetables or plants rich in antioxidants, can lead to prevention of CVDs. Because low cost and less adverse

effects, the use of traditional medicine is preferred over chemical drugs (Kumar et al., 2012). The protective effects of these natural products can be attributed to the presence of flavonoids, anthocyanins, and other phenolic compounds (Zhang and Wang, 2002). In this regard, GA due to free radical scavenger and antioxidant action, received much attention (Stanely Mainzen Prince et al., 2009).

GA (Figure 1) belongs to the larger group of plant polyphenols known as gallotannins. It is found in vegetables, fruits (Kawada et al., 2001), tea leaves, grapes, blackberry, and gallnuts (Choubey et al., 2015). It has multiple biological effects such as antioxidant (Soong and Barlow, 2006), anti-allergic (Kim et al., 2005) antimicrobial (Chanwitheesuk et al., 2007), anticancer (Wang et al., 2014), anti-ulcer (Sen et al., 2013), and neuroprotective properties (Mansouri et al., 2013).




Figure 1. Chemical structure of gallic acid (3, 4, 5-trihydroxy benzoic acid).

Furthermore, it has shown beneficial effects in animal model of metabolic diseases (Doan et al., 2015). In addition, GA has antihyperglycemic (Huang et al., 2016), and lipid homeostasis (Chao et al., 2014) actions.

While considerable evidence support that GA is a cardioprotective agent (Appeldoorn et al., 2005, Kee et al., 2014, Jin et al., 2017), no review article in this regard was published. Therefore, the aim of this review is to discuss the molecular mechanisms underlying GA effect against CVDs as summarized in Tables 1 and 2.

Table 1. Effect of different doses of gallic acid on CVDs.

Study design	Intervention/Duration/Animal/Route	Reference
Isoproterenol-induced cardiac hypertrophy and fibrosis	100 mg/kg/1 week pretreatment and 2 weeks co-administration with ISP/mice/ip	(Ryu et al., 2016)
Doxorubicin-induced myocardial toxicity	15 and 30 mg/kg/ 2 weeks/rat/po	(Kulkarni and Swamy, 2015)
CaCl ₂ -induced arrhythmia	10, 30, 50 mg/kg/10 days/rat/gavage	(Dianat et al., 2013)
Cardiac hypertrophy and spontaneously hypertension Cardiac IR injury	320 mg/kg/16 weeks/rat/po 7.5,15,30 mg/kg/10 days/rat/gavage	(Jinet al., 2017) (Badavi et al., 2014)
IR following alloxan-induced diabetes	25 mg/kg/8 weeks/rat/gavage	(Ramezani-Aliakbari et al., 2017)
Isoproterenol-induced myocardial infarction	15 mg/kg/10 days/rat/po	(Stanely Mainzen Prince et al., 2009)
Diabetes-induced myocardial dysfunction	100 mg/kg/8 weeks/rat/p.o 25,50,	(Patel and Goyal, 2011)
Advanced glycation end Products-induced cardiac remodeling	25 mg/kg/30 days/rat/gavage	(Umadevi et al., 2014)
L-NAME-induced hypertension Cardiac remodeling, and fibrosis	50,100 mg/kg/3 weeks/mice/ip 100 mg/kg/ip	(Jin et al., 2017)
Immobilization-induced stress in myocardium	10 mg/kg/3 weeks/rat/ip	(Rather and Saravanan, 2013)
Cirrhosis-induced ECG changes	30 mg/kg/28 days/rat/ gavage	(Badavi et al., 2016)
Diabetes-induced MVB dysfunction	mg/kg/6 weeks/rat/ gavage and 40 20	(Badavi et al., 2017)

Materials and Methods

Online databases including Science Direct, Scopus, PubMed, and Scientific Information Database between 1993 and 2018 using the keywords Gallic acid, Cardiovascular diseases and Molecular mechanisms.

Results

The effect of gallic acid on myocardial infarction

Myocardial infarction (MI) is one of the major causes of death among CVDs which occur when myocardial oxygen demand is higher than oxygen supply and eventually leads to cardiomyocyte necrosis (Stanely Mainzen Prince et al., 2009). MI affects mechanical, electrical, structural and biochemical properties of the heart (Bakheet et al., 2014).

A method for diagnosis of cardiac injury is measurement of the cardiac marker enzymes such as aspartate transaminase (AST), alanine transaminase (ALT), creatine kinase (CK), creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH), and cardiac troponin T (cTnT) in serum. Among these, cTnT is a very sensitive, and specific parameter in detecting MI (Janota, 2014).

It was reported that pretreatment with GA decreased the levels of these enzymes in serum probably due to reduction of myocardial damage and thereby limiting the leakage of these enzymes from myocardium (Priscilla and Prince, 2009). GA may protect the heart by inhibiting lipid peroxidation because it scavenges the superoxide, and hydroxyl radicals (Jadon et al., 2007). In addition, GA inhibits the lysosomal membrane destruction following isoproterenol-induced heart damage, and recovered the functions of this organelle to near normal levels. This activity of GA was attributed to antilipoperoxidative, and antioxidant characteristics of this agent (Stanely Mainzen Prince et al., 2009).

Effect of gallic acid on vascular diseases

The normal endothelium of vessel regulates tone, and structure, and exerts anticoagulant, and antiplatelet properties (Sandoo et al., 2010). The maintenance of vascular tone is done by the release of multiple vasodilator, and vasoconstrictor agents. The most important vasodilators are nitric oxide (NO), endothelium-derived relaxing factor (EDRF), prostacyclin, and bradykinin. The endothelium also produces vasoconstrictor substances, such as endothelin and angiotensin II (Bakheet et al., 2014). In hypertension (HTN), the balance between vasodilators and vasoconstrictors is disrupted (Nadar et al., 2004).

HTN is a public problem all over the world (Jin., et al. 2017), and is regarded as a major cardiovascular risk factor which leads to atherosclerosis, cardiac hypertrophy, and heart failure (Jin et al., 2017). It is a major cause of the occurrence of CVDs and left ventricular hypertrophy (LVH) (Verdecchia et al., 2004). Other pathophysiologic events of HTN are activation of the renin-angiotensin-aldosterone system (RAAS), endothelial dysfunction, salt consumption, and oxidative stress (Oparil et al., 2003).

In HTN, oxidative stress promotes vascular remodeling, as well as fibrosis, and hypertrophy (Harvey et al., 2016). Free radical oxygen species influence on nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox) (Jin et al., 2017). Nox2 is activated by angiotensin II or endothelin-1 (Sag et al., 2014). Nox2 has a more important role compared to the other Noxs in mediating oxidative stress response in cardiomyocytes. It has been reported that GA attenuated cardiac Nox2 transcript level, and Nox2 protein expression in spontaneously hypertensive rats (SHRs) (Jin et al., 2017).

GA also down-regulates two constituents of RAAS including the angiotensin II receptor and angiotensin II-converting enzyme. Besides, GA decreased AT1 mRNA levels in the aorta, heart, and kidney cortex of SHRs but enhanced ACE1

mRNA levels in SHR aortas (Jin et al., 2017). GA also decreased HTN via a vasorelaxant effect by increased NO levels following activating phosphorylation of endothelial nitric oxide synthase (eNOS) (Kang et al., 2015).

Furthermore, GA down-regulates Ca²⁺/calmodulin-dependent protein kinase II δ (CaMKII δ) expression and apoptosis-related genes such as Bcl-2- associated X

protein (BAX), and p53 mRNA levels in SHR (Jin et al., 2017). GA also decreases vascular calcification through the bone morphogenetic proteins (BMP2)–small mother against decapentaplegic (smad)1/5/8 signaling pathway inhibition, suggesting that GA may have a protective role in vascular diseases (Kee et al., 2014). as summarized in Figure 2.




Figure 2. Schematic presentation of the molecular mechanisms underlying GA effects on HTN.

Effect of gallic acid on ECG abnormalities

Arrhythmias determined by irregularities at impulse production, impulse conduction or composition of both (Dianat et al., 2013). The most important etiologies of cardiac arrhythmias are MI, valvular heart problems, electrolyte disturbances, metabolic syndrome, and drug overdose (Zern and Fernandez, 2005).

Ventricular fibrillation (VF) and ventricular tachycardia (VT) are two major etiologies of mortality in developing countries (Balasundaram et al., 2013). VF is a serious arrhythmia which is manifested by undistinguished rhythm, whereas, VT is a regular arrhythmias, and occur when the frequency of premature ventricular beat (PVB) becomes ≥ 3 -4 beats/min (John et al., 2012).

Reperfusion-induced arrhythmias such as VT, VF, and PVB are the most important

causes of cardiac death which happen due to excessing production of ROS, and calcium during first time of reperfusion (Zhao et al., 2010). It has been shown that GA decreases the incidence of VF, VT, and PVB following CaCl₂-induced arrhythmia (Dianat et al., 2013). This action is related to increased levels of vitamins C and E as well as glutathione, which scavenge ROS, superoxide anions, and hydroxyl radicals (Priscilla and Prince, 2009). Also, it was shown that GA through attenuating platlet aggregation has protective actions against arrhythmias (Appeldoorn et al., 2005).

Prolonged QT interval is an electerocardiographic manifestation in underlying of cirrhosis (Alqahtani et al., 2008). Furthermore, it has been indicated that QTc interval prolongation can be associated with enhancement of occurrence of ventricular arrhythmias (De et al., 2003). Although, in this regard, mechanism is not

clear yet, there seems to be a strong correlation between QTc prolongation and cirrhosis representing QTc interval as the important ECG finding in cirrhosis cardiomyopathy (Carey and Douglas, 2005). It was revealed that GA increased

QRS voltage, and reduction of QTc interval in a rat model of liver cirrhosis following induction of bile duct ligation (Badavi et al., 2016).

Table 2. The mechanisms involved in gallic acid effects against cardiovascular diseases.

Study design	Effects	References
Isoproterenol-induced cardiotoxicity	↓ECM proteins (collagens type I and III), CTGF, TGF-β1 ↓CPK, CK-MB, and LDH, cTnT ↓HDAC1 or HDAC2 ↓ANP, BNP, βMHC ↓p-JNKs, p-ERK, ↓p-Smad3	(Stanely Mainzen Prince et al., 2009, Priscilla and Prince, 2009; Bakheet et al., 2014; Umadevi et al., 2014; Ryu et al., 2016; Jin et al., 2017)
Doxorubicin-induced cardiotoxicity	↓CK-MB, LDH, LDL-c, VLDL, TG, ↑HDL ↑Levels of GSH, SOD, CAT ↓MDA activity Elimination of ↑ST segment ↓P wave, QRS complex ↓BP ↓Histopathological changes	(Kulkarni and Swamy, 2015)
ECG abnormalities	↓ Incidence VT, VF, PVB ↓QT interval prolongation, ↑QRS voltage	(Dianat et al., 2013; Badavi et al., 2016)
Cardiac hypertrophy and spontaneously hypertensive	↓Serum levels of CPK, CK-MB, LDH, cTnT ↓Cardiac hypertrophy, infarct size Modulatory effects on LVP, LVEDP, LVSP, LVDP, RPP ↓p-JNKs, p-ERK & GATA6 downregulation	(Umadevi et al., 2014; piao et al., 2017)
Cardiac ischemia-reperfusion injury	↓CPK, CK-MB, LDH ↑SOD, CAT, GPx activity & ↓MDA level ↓Hypertrophy, infarct size Preserve the cell membrane and mitochondria & ↓mPTPs opening ↑coronary flow	(Badavi et al., 2014; Dianat et al., 2014; Badavi et al., 2017)
Diabetes-induced myocardial dysfunction	↓CPK, CK-MB, and LDH, cTnT, BS ↑SOD, CAT, GPx ↑LVP, LVEDP, LVSP, LVDP, RPP ↑SOD, CAT, GPx, ↓MDA, ↑NO ↓ Hypertrophy, infarct size & ↑vasodilatory response	(Patel and Goyal, 2011; Ramezani-Aliakbari et al., 2017)
Immobilization induced stress in myocardium	↑SOD, CAT, GPx activity ↓LPO markers (TBARS, LOOH) Preserved the structural integrity of heart	Rather and Saravanan) (2013)

Effect of gallic acid on cardiac ischemia/reperfusion injury

Ischemia-reperfusion (I/R) injury results in cellular insults in an organ following ischemia which further aggravate during the re-supply of blood circulation (Akbari et al., 2018). It substantially affects hepatic (Akbari et al., 2017), renal (Mard et al., 2017), gastric (Odukanmi et al., 2017), brain (Sanderson et al., 2013), and cardiac functions (Hausenloy and Yellon, 2013). The pathophysiology of ischemia-induced cell damage is calcium dyshomeostasis, activation of phospholipases, proteases, and endonucleases and generation of ROS

which induce oxidative stress and affect cellular macromolecules (Rhodena et al., 2002), activating the ROS-dependent processes, opening of mitochondrial permeability transition pore (mPTP) (Collard and Gelman, 2001), and electron transformation chain (ETC) disruption (Paradies et al., 1999).

The overproduction of ROS in the absence of antioxidant system has been regarded as a possible mechanism in the pathogenesis of I/R injury (Arabi et al., 2017). Although, ROS at physiological concentrations is useful for cardiac molecular signaling pathways, but at the

high pathological levels induces inverse effects on this organ. Furthermore, production of ROS, during ischemia and at the early stage of re-oxygenation can have negative impacts on the heart (Popov et al., 2017). Reperfusion, in the setting of angioplasty and thrombolysis, reestablishes coronary blood supply and decreases infarct size, but initiates damage to cardiomyocyte (i.e. I/R insult) (Chi et al., 2017).

It was shown GA preserves the cell membrane and mitochondria against ROS-induced damage by preventing mPTP opening (Badavi et al., 2014). The antioxidant enzymes of SOD, CAT, and GPx have protective effect against I/R-induced damage (Akbari et al., 2017). Furthermore, studies showed that GA through increasing the capacity of endogenous antioxidant system protected the rat isolated heart against this injury (Badavi et al., 2014; Dianat et al., 2014).

Effect of gallic acid on cardiac remodeling

Cardiac remodeling was first discovered in regional dilatation and thinning of infarcted myocardium in rats (Hochman and Bulkley, 1982). This term was attributed to alterations in the cardiac structure such as cardiomyocyte loss, cardiac hypertrophy, and changes of extracellular matrix, metabolic problems, and mitochondrial impairment. Cardiac remodeling leads to cardiac hypertrophy, fibrosis and a progressive impairment in contractility and relaxation in the heart and eventually cardiac failure (Schirone et al., 2017).

Cardiac hypertrophy is a manifestation of hypertrophic cardiomyopathy (HCM). Dilated cardiomyopathy (DCM) is a type of HCM and contributes to heart fibrosis (Inagaki et al., 2008). It is manifested by enhancement of cardiac mass, and protein synthesis rate, sarcomeric reorganization, and activation of atrial natriuretic peptide, brain natriuretic peptide, β -myosin heavy chain, and skeletal α -actin. It is usually associated with fibrosis which is

determined by aggregation of collagen type I and fibronectin (Jeong et al., 2005). Multiple hypertrophic parameters initiate several signaling pathways by stimulating downstream targets. One of the most important pathways is the mitogen-activated protein kinase (MAPK) (Rose et al., 2010) that divides into p38 kinases, c-Jun N-terminal kinase (JNK) and extracellular signal regulated kinase (ERK). It has been reported that these kinases decreased by GA pretreatment (Ryu et al., 2016). Furthermore, GA prevents β -adrenergic agonist-induced cardiac hypertrophy (Ryu et al., 2016). GA also decreased the increased heart weight to body weight ratio in streptozotocin-induced diabetic rats (Patel and Goyal, 2011).

GATA6 is a major hypertrophic regulator and its overexpression induces cardiac hypertrophy both in vivo and in vitro (Liang et al., 2001). It was revealed that attenuation of myocardial hypertrophy by GA accompany with GATA6 downregulation. GA also downregulates cardiac Nox2 expression and Nox2-induced oxidative stress response via suppression of GATA6 or by affecting DNA-binding activity of GATA6 (Jin et al., 2017).

The term cardiac fibrosis is attributed to aggregation of types I and III collagen, and extracellular matrix (ECM) crosslinking which lead to stiffening of the cardiac chamber, and disturbances in cardiac elasticity and diastolic function (Segura et al., 2014). Taken together, the progression of fibrosis requires increased synthesis of matrix metalloproteinases (MMPs) (Kandalam et al., 2011), activation of profibrotic mediators, such as TGF- β , α -smooth muscle actin (α -SMA), platelet-derived growth factor (PDGF), cytokines (Kong et al., 2014), and differentiation of fibroblasts into myofibroblasts (Wang et al., 2003).

It was shown that GA effectively attenuated the cardiac fibrosis in the pre-established HTN mice. This effect may be related to downregulation of ECM proteins collagens of type I and III, and connective

tissue growth factor (CTGF). Furthermore, GA decreased the NG-nitro-L-arginine methyl ester (L-NAME) induced transforming growth factor beta 1 (TGF- β 1) which is a cytokine and mediator in fibroblast proliferation and ECM accumulation (Pohlers et al., 2009).

TGF- β 1-small mother against decapentaplegic 3 (Smad3) is another signaling network which contributes to fibrosis formation. Smad2 and Smad3 are downstream mediators of TGF- β . In cytoplasm, Smad2 and Smad3 are phosphorylated by activated type I receptors, then they bind Smad4. This complex is then transferred to the nucleus. Smad2 protects fibrosis (Meng et al., 2010), whereas Smad3 activates it (Qin et al., 2011). The correlation between MAPK and TGF- β 1-Smad3 axis has been reported. GA conserves cardiac hypertrophy and fibrosis via regulation of the MAPK signaling pathway and Smad3-mediated collagen type I expression (Ryu et al., 2016).

Histone acetyltransferases (HATs) are a category of enzymes that acetylate histones. An imbalance between HATs and histone deacetylases (HDACs) can lead to pathological disorders. Furthermore, alterations in HDAC amounts and enzyme activity are implicated in a variety of diseases, including cardiac hypertrophy, and fibrosis. It was shown that antihypertrophic or antifibrosis effect of GA is mediated by the regulation of HDAC1 or HDAC2 (Jin et al., 2017).

Effect of gallic acid on drugs-induced cardiotoxicity

Cardiotoxicity is a well-known complication of multiple drugs which (Meinardi et al., 2000) includes a broad range of cardiac characteristics from little alterations in several parameters such as blood pressure (BP) and arrhythmias to cardiomyopathy (Arola et al., 2000). Doxorubicin (DOX)-induced cardiomyopathy is related with an elevation oxidative stress in the heart which is manifested by lipid peroxidation, decreased

antioxidants capacity and sulfhydryl groups levels (Octavia et al., 2012).

DOX is one of the most important anti-neoplastic agents to treat a number of diseases; however, its use is limited owing to the dose-dependent cardiotoxicity which leads to dilated cardiomyopathy with fetal congestive heart failure (Mohan et al. 2006). Electrocardiograph (ECG) changes are the major findings for diagnosis of cardiac damage. The ECG findings following DOX toxicity are elevation of ST segment, reduction of P wave, QRS complex, and prolongation of QT interval (Octavia et al., 2012).

Pretreatment with GA eliminated DOX-induced altered ECG, and reduced serum concentrations of CK-MB, LDH, low-density lipoprotein-cholesterol (LDL-c), and serum triglycerides. This effect may be related to preservation of the normal structure of cardiac myocytes due to restoring the antioxidants of GSH, SOD, and CAT, and hence decreasing the entrance of mentioned parameters to the blood circulation. The lipid-lowering action of GA is attributed to suppression of hepatic cholesterol biosynthesis, increased fecal bile secretion and activation of receptor-mediated catabolism of LDL-c, and decreases in serum levels of triglycerides, LDL-c, very low-density lipoprotein-cholesterol through inhibiting lipogenesis (Kulkarni and Swamy, 2015).

Among catecholamines, isoproterenol (ISP), is a well-known drug for induction of MI in animal models for investigation of the effects of drugs on cardiac function (Stanely Mainzen Prince et al., 2009). It has been shown that in mice, infusion of ISP (up to 2 weeks) leads to cardiac hypertrophy which is manifested by enhancement of wall thickness of left ventricle (LV) (Ryu et al., 2016). Mechanisms suggested for explaining ISP-induced cardiac insult are production of abundant cytotoxic free radicals and increased activities of lysosomal enzymes (Stanely Mainzen Prince et al., 2009).

Excessive production of free radicals may result in the loss of function and integrity of myocardial membranes (Priscilla and Prince, 2009). GA preserves the integrity of lysosomal membrane by maintaining the activities of lysosomal enzymes in the serum and heart due to antilipoperoxidative and antioxidant impacts of its (Stanely Mainzen Prince et al., 2009; Umadevi et al., 2012). In addition, it was reported that GA decreased the ISP-induced phosphorylation JNK1/2 and ERK1/2 in vivo (Ryu et al., 2016). Furthermore, it was presented that administration of GA suppressed collagen aggregation due to ISP in mice and it attenuated the mRNA and protein expression of fibronectin, collagen type I, and α -smooth muscle actin (Ryu et al., 2016).

Effect of gallic acid on DM-induced CVDs

Diabetic mellitus (DM) is a metabolic problem which is associated with high blood glucose owing to disturbance in insulin secretion, insulin impact, or both (Olusoji et al., 2017) which accompany CVDs (Perazzoli et al., 2017). NO, prostacyclin and endothelium-derived hyperpolarization are major signaling pathways contributing to relaxation of endothelium (Ng et al., 2017).

It was reported that chronic DM affects endothelial function, but not vascular smooth muscle which is associated with enhancement of oxidative stress (Pannirselvam et al., 2005).

It was shown that endothelium-dependent vasodilatory response of the mesenteric vascular bed (MVB) to histamine, is dramatically attenuated and it is related to both NO and prostaglandin pathways (Pannirselvam et al., 2005).

The incidence of myocardial dysfunction is two to five times higher in diabetic patients than nondiabetics. Hyperglycemia, hyperlipidemia, oxidative stress, and production of advanced glycation end products have all been contributed to the pathogenesis of diabetes

(Patel and Goyal, 2011). It was shown that DM increases oxidative stress and reduces antioxidant capacity in I/R hearts (Suwalsky et al., 2016).

GA increased the decreased hemodynamic parameters such as left ventricular pressure (LVP), left ventricular end diastolic pressure (LVEDP), left ventricular end diastolic and systolic pressure (LVEDP, and LVSP) and Left ventricular developed pressure (LVDP), rate pressure product (RPP), and antioxidant capacity of SOD, CAT, and GPx as well as NO. Indeed, this agent decreased infarct size, and cardiac marker enzymes including CPK, CK-MB, and LDH, and cTnT following I/R injury in hearts isolated from rats with alloxan-induced DM. Other elevated parameters such as blood sugar (BS), and MDA level also decreased in this experimental model (Ramezani-Aliakbari et al., 2017).

Discussion

CVDs including coronary artery disease, hypertension, arrhythmia, heart failure, myocardial infarction, cardiac remodeling, and cardiotoxicity are the major cause of mortality and have become one of the most important health challenges in developing countries. The pathophysiology of CVDs are overproduction of toxic lipid metabolites, elevation of cardiac marker enzymes, hemodynamic parameters disturbances, histopathological alterations and decreasing of antioxidant activity. In ethnopharmacology science, study on natural herbal products with different mechanisms is aimed for progress of new medication because chemical drugs have various disadvantages.

GA is one of the most important herbal products which has beneficial effects on CVDs. GA has protective effects on drugs-induced cardiotoxicity through decreasing the ECM proteins, CTGF, TGF- β 1 CPK, CK-MB, cTnT, LDH, LDL-c, VLDL, TG,

HDAC1 or HDAC2, ANP, BNP, β MHC, p-JNKs, p-ERK, p-Smad3, MDA levels, and histopathological alterations and increasing levels of HDL, GSH, SOD, and CAT. Furthermore, GA attenuates ECG abnormalities via decreasing incidence of VT, VF, PVB, QT interval prolongation, and elevation of QRS voltage.

The effect of GA on cardiac ischemia-reperfusion injury attributed to mitigating levels of CPK, CK-MB, LDH, MDA, infarct size, mPTPs opening and preservation of cell membrane, enhancement of SOD, CAT, GPx activity and coronary blood flow. In addition, GA has regulatory action on cardiac hypertrophy and hypertension through reducing serum levels of CPK, CK-MB, LDH, cTnT, cardiac hypertrophy, infarct size, and down-regulating of p-JNKs, p-ERK, GATA6 and modulating of hemodynamic parameters including LVP, LVEDP, LVSP, LVDP, RPP. On the other hand, protective action of GA on diabetes-induced myocardial dysfunction attributed to attenuating of serum levels of CPK, CK-MB, and LDH, cTnT, BS, and decreasing MDA levels, myocardial hypertrophy, infarct size and increasing antioxidant activity of SOD, CAT, GPx, and hemodynamic parameters such as LVP, LVEDP, LVSP, LVDP, RPP and vasodilatory response. GA via increasing SOD, CAT, and GPx activities, decreasing LPO markers, and preserving of the structural integrity of heart tissues also reduces immobilization induced stress in myocardium.

GA also showed protective role against vascular diseases through molecular mechanisms of increasing NO level, down-regulation of protein expression of Nox2, angiotensin II, angiotensin II-converting enzyme, CaMKII δ , and apoptotic genes including BAX, and p53 mRNA level, as well as decreasing of vascular calcification through BMP2-smad1/5/8 signaling pathway inhibition.

Acknowledgment

The author would like to gratefully acknowledge the financial support of Yasuj University of Medical Sciences, Yasuj, Iran.

Conflict of interest

None of the authors have any conflict of interest.

References

- Akbari G, Ali Mard S, Veisi A. 2018. A comprehensive review on regulatory effects of crocin on ischemia/reperfusion injury in multiple organs. *Biomed Pharmacother*, 99: 664-670.
- Akbari G, Mard SA, Dianat M, Mansouri M. 2017. The hepatoprotective and microRNAs downregulatory effects of crocin following hepatic ischemia-reperfusion injury in rats. *Oxid Med Cell Longev*, 2017: 1702967.
- Alqahtani SA, Fouad TR, Lee SS. 2008. Cirrhotic cardiomyopathy. *Semin Liver Dis*, 28:59-69.
- Appeldoorn CC, Bonnefoy A, Lutters BC, Daenens K, van Berkel TJ, Hoylaerts MF, Biessen EA. 2005. Gallic acid antagonizes P-selectin-mediated platelet-leukocyte interactions: Implications for the French paradox. *Circulation*, 111: 106-112.
- Arabi M, Ghaedi M, Ostovan A. 2017. Synthesis and application of in-situ molecularly imprinted silica monolithic in pipette-tip solid-phase microextraction for the separation and determination of gallic acid in orange juice samples. *J Chromatogr B Analyt Technol Biomed Life Sci*, 1048: 102-110.
- Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Voipio-Pulkki 2000. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. *Cancer res*, 60: 1789-1792.
- Badavi M, Barzegar F, Dianat M, Mard SA. 2016. Evaluation of the effect of gallic acid on QT interval prolongation and serum bilirubin in rat model of liver cirrhosis. *RJPBCS*, 7: 586-592.
- Badavi M, Bazaz A, Dianat M, Sarkaki A. 2017. Gallic acid improves endothelium-dependent vasodilatory response to

- histamine in the mesenteric vascular bed of diabetic rats. *J Diabetes*, 9: 1003-1011.
- Badavi M, Sadeghi N, Dianat M, Samarbafzadeh A. 2014. Effects of gallic Acid and cyclosporine a on antioxidant capacity and cardiac markers of rat isolated heart after ischemia/reperfusion. *Iran Red Crescent Med J*, 16: e16424.
- Badavi M, Sadeghi N, Dianat M, Samarbafzadeh A. 2017. Gallic acid and cyclosporine mixture and their effects on cardiac dysfunction induced by ischemia/reperfusion and eNOS/iNOS expression. *Int J Cardiovasc Sci*, 30: 207-218.
- Bakheet MS, Soltan S, Gadalla A, Haredy HH, Shakoor MA. 2014. Antioxidants (vitamin E and gallic acid) as valuable protective factors against myocardial infarction. *Basic Res J Med Clin Sci*, 11: 109-122.
- Balasundaram K, Masse S, Nair K, Umopathy K. 2013. A classification scheme for ventricular arrhythmias using wavelets analysis. *Med Biol Eng Comput*, 51: 153-164.
- Carey EJ, Douglas DD. 2005. Effects of orthotopic liver transplantation on the corrected QT interval in patients with end-stage liver disease. *Dig Dis Sci*, 50: 320-323.
- Chanwitheesuk A, Teerawutgulrag A, Kilburn J D, Rakariyatham N. 2007. Antimicrobial gallic acid from *Caesalpinia mimosoides* Lamk. *Food Chem*, 100: 1044-1048.
- Chao J, Huo TI, Cheng HY, Tsai JC, Liao JW, Lee MS, Qin XM, Hsieh MT, Pao LH, Peng WH. 2014. Gallic acid ameliorated impaired glucose and lipid homeostasis in high fat diet-induced NAFLD mice. *PLoS one*, 9: e96969.
- Chi C, Li X, Zhang Y, Chen L, Li L, Wang Z. 2017. Digestibility and supramolecular structural changes of maize starch by non-covalent interactions with gallic acid. *Food Funct*, 8: 720-730.
- Choubey S, Varughese LR, Kumar V, Beniwal V. 2015. Medicinal importance of gallic acid and its ester derivatives: a patent review. *Pharm Pat Anal*, 4: 305-315.
- Collard CD, Gelman S. 2001. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. *Anesthesiology*, 94: 1133-1138.
- De BK, Majumdar D, Das D, Biswas PK, Mandal SK, Ray S, Bandopadhyay K, Das TK, Dasgupta S, Guru S. 2003. Cardiac dysfunction in portal hypertension among patients with cirrhosis and non-cirrhotic portal fibrosis. *J Hepatol*, 39: 315-319.
- Dianat M, Akbari G, Badavi M. 2013. Antidysrhythmic effects of gallic acid on cacl2-induced arrhythmia in rat. *Int J Res Dev Pharm L Sci*, 2: 686-689.
- Dianat M, Sadeghi N, Badavi M, Panahi M, Taheri Moghadam M. 2014. Protective effects of co-administration of gallic Acid and cyclosporine on rat myocardial morphology against ischemia/reperfusion. *Jundishapur J Nat Pharm Prod*, 9: e17186.
- Doan KV, Ko CM, Kinyua AW, Yang DJ, Choi YH, Oh IY, Nguyen NM, Ko A, Choi JW, Jeong Y, Jung MH, Cho WG, Xu S, Park KS, Park WJ, Choi SY, Kim HS, Moh SH, Kim KW. 2015. Gallic acid regulates body weight and glucose homeostasis through AMPK activation. *Endocrinology*, 156: 157-168.
- Harvey A, Montezano AC, Lopes RA, Rios F, Touyz RM. 2016. Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications. *Can J Cardiol*, 32: 659-668.
- Hausenloy DJ, Yellon DM. 2013. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. *J Clin Invest*, 123: 92-100.
- Hochman JS, Bulkley BH. 1982. Expansion of acute myocardial infarction: an experimental study. *Circulation*, 65: 1446-1450.
- Huang DW, Chang WC, Wu JS, Shih RW, Shen SC. 2016. Gallic acid ameliorates hyperglycemia and improves hepatic carbohydrate metabolism in rats fed a high-fructose diet. *Nutr Res*, 36: 150-160.
- Inagaki K, Koyanagi T, Berry NC, Sun L, Mochly-Rosen D. 2008. Pharmacological inhibition of epsilon-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure. *Hypertension*, 51: 1565-1569.
- Jadon A, Bhadauria M, Shukla S. 2007. Protective effect of *Terminalia bellerica* Roxb. and gallic acid against carbon tetrachloride induced damage in albino rats. *J Ethnopharmacol*, 109: 214-218.
- Janota T. 2014. Biochemical markers in the diagnosis of myocardial infarction. *Cor et Vasa* 56: e304-e310.

- Jeong MY, Kinugawa K, Vinson C, Long CS. 2005. A β dissociates cardiac myocyte hypertrophy and expression of the pathological gene program. *Circulation*, 111: 1645-1651.
- Jin L, Lin MQ, Piao ZH, Cho JY, Kim GR, Choi SY, Ryu Y, Sun S, Kee HJ, Jeong MH. 2017. Gallic acid attenuates hypertension, cardiac remodeling, and fibrosis in mice with NG-nitro-L-arginine methyl ester-induced hypertension via regulation of histone deacetylase 1 or histone deacetylase 2. *J Hypertens*, 35: 1502-1512.
- Jin L, Piao ZH, Liu CP, Sun S, Liu B, Kim GR, Choi SY, Ryu Y, Kee HJ, Jeong MH. 2017. Gallic acid attenuates calcium calmodulin-dependent kinase II-induced apoptosis in spontaneously hypertensive rats. *J Cell Mol Med*, 22:1517-1526.
- Jin L, Piao ZH, Sun S, Liu B, Kim GR, Seok YM, Lin MQ, Ryu Y, Choi SY, Kee HJ, Jeong MH. 2017. Gallic acid reduces blood pressure and attenuates oxidative stress and cardiac hypertrophy in spontaneously hypertensive rats. *Sci Rep*, 7: 15607.
- John RM, Tedrow UB, Koplak BA, Albert CM, Epstein LM, Sweeney MO, Miller AL, Michaud GF, Stevenson WG. 2012. Ventricular arrhythmias and sudden cardiac death. *Lancet*, 380: 1520-1529.
- Kandalam V, Basu R, Moore L, Fan D, Wang X, Jaworski DM, Oudit GY, Kassiri Z. 2011. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. *Circulation*, 124: 2094-2105.
- Kang N, Lee JH, Lee W, Ko JY, Kim EA, Kim JS, Heu MS, Kim GH, Jeon YJ. 2015. Gallic acid isolated from *Spirogyra* sp. improves cardiovascular disease through a vasorelaxant and antihypertensive effect. *Environ Toxicol Pharmacol*, 39: 764-772.
- Kaul N, Kaul N, Siveski-Iliskovic N, Hill M, Slezak J, Singal PK. 1993. Free radicals and the heart. *J Pharmacol Toxicol Methods*, 30: 55-67.
- Kawada M, Ohno Y, Ri Y, Ikoma T, Yuugetu H, Asai T, Watanabe M, Yasuda N, Akao S, Takemura G, Minatoguchi S, Gotoh K, Fujiwara H, Fukuda K. 2001. Anti-tumor effect of gallic acid on LL-2 lung cancer cells transplanted in mice. *Anticancer drugs*, 12: 847-852.
- Kee HJ, Cho SN, Kim GR, Choi SY, Ryu Y, Kim IK, Hong YJ, Park HW, Ahn Y, Cho JG, Park JC, Jeong MH. 2014. Gallic acid inhibits vascular calcification through the blockade of BMP2–Smad1/5/8 signaling pathway. *Vascul Pharmacol*, 63: 71-78.
- Kim SH, Jun CD, Suk K, Choi BJ, Lim H, Park S, Lee SH, Shin HY, Kim DK, Shin TY. 2005. Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells. *Toxicol Sci*, 91: 123-131.
- Kong P, Christia P, Frangogiannis NG. 2014. The pathogenesis of cardiac fibrosis. *Cell Mol Life Sci*, 71: 549-574.
- Kulkarni J, Swamy AV. 2015. Cardioprotective effect of gallic acid against doxorubicin-induced myocardial toxicity in albino rats. *Indian J Health Sci Biomed Res*, 8: 28-35.
- Kumar S, Meenu S, Kumar V, Prakash O, Arya R, Rana M, Kumar D. 2012. Traditional medicinal plants curing diabetes: A promise for today and tomorrow. *Asian J Tradit Med*, 7: 178-188.
- Liang Q, De Windt LJ, Witt SA, Kimball TR, Markham BE, Molkentin JD. 2001. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. *J Biol Chem* 276: 30245-30253.
- Mansouri MT, Farbood Y, Sameri MJ, Sarkaki A, Naghizadeh B, Rafeirad M. 2013. Neuroprotective effects of oral gallic acid against oxidative stress induced by 6-hydroxydopamine in rats. *Food chem*, 138: 1028-1033.
- Mard SA, Akbari G, Mansouri E, Parsanahad M. 2017. Renoprotective effect of crocin following liver ischemia/reperfusion injury in Wistar rats. *Iran J Basic Med Sci*, 20: 1172-1177.
- Meinardi MT, Gietema JA, van Veldhuisen DJ, van der Graaf WT, de Vries EG, Sleijfer DT. 2000. Long-term chemotherapy-related cardiovascular morbidity. *Cancer Treat Rev*, 26: 429-447.
- Meng XM, Huang XR, Chung AC, Qin W, Shao X, Igarashi P, Ju W, Bottinger EP, Lan HY. 2010. Smad2 protects against TGF- β /Smad3-mediated renal fibrosis. *J Am Soc Nephrol*, 21: 1477-1487.
- Mohan IK, Kumar KV, Naidu MU, Khan M, Sundaram C. 2006. Protective effect of CardiPro against doxorubicin-induced cardiotoxicity in mice. *Phytomedicine*, 13: 222-229.

- Nadar S, Blann AD, Lip GY. 2004. Endothelial dysfunction: methods of assessment and application to hypertension. *Curr Pharm Des*, 10: 3591-3605.
- Ng HH, Leo CH, Prakoso D, Qin C, Ritchie RH, Parry LJ. 2017. Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes. *Sci Rep*, 7: 39604.
- Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. 2012. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. *J Mol Cell Cardiol*, 52: 1213-1225.
- Odukanmi OA, Salami AT, Ashaolu OP, Adegoke AG, Olaleye SB. 2017. Kolaviron attenuates ischemia/reperfusion injury in the stomach of rats. *Appl Physiol Nutr Metab*, 43: 30-37.
- Olusoji MJ, Oyeyemi OM, Asenuga ER, Omobowale TO, Ajayi OL, Oyagbemi AA. 2017. Protective effect of Gallic acid on doxorubicin-induced testicular and epididymal toxicity. *Andrologia*, 49: e12635.
- Oparil S, Zaman MA, Calhoun DA. 2003. Pathogenesis of hypertension. *Ann Intern Med*, 139: 761-776.
- Pannirselvam M, Wiehler WB, Anderson T, Triggler CR. 2005. Enhanced vascular reactivity of small mesenteric arteries from diabetic mice is associated with enhanced oxidative stress and cyclooxygenase products. *Br J Pharmacol*, 144: 953-960.
- Paradies G, Petrosillo G, Pistolese M, Di Venosa N, Serena D, Ruggiero FM. 1999. Lipid peroxidation and alterations to oxidative metabolism in mitochondria isolated from rat heart subjected to ischemia and reperfusion. *Free Radic Biol Med*, 27: 42-50.
- Patel SS, Goyal RK. 2011. Cardioprotective effects of gallic acid in diabetes-induced myocardial dysfunction in rats. *Pharmacognosy Res*, 3: 239-245.
- Perazzoli MR, Perondi CK, Baratto CM, Winter E, Creczynski-Pasa TB, Locatelli C. 2017. Gallic acid and dodecyl gallate prevents carbon tetrachloride-induced acute and chronic hepatotoxicity by enhancing hepatic antioxidant status and increasing p53 expression. *Biol Pharm Bull*, 40: 425-434.
- Pohlert D, Brenmoehl J, Löffler I, Müller CK, Leipner C, Schultze-Mosgau S, Stallmach A, Kinne RW, Wolf G. 2009. TGF- β and fibrosis in different organs—molecular pathway imprints. *Biochim Biophys Acta*, 1792: 746-756.
- Popov M, Hejtmánková A, Kotíková Z, Střáfková R, Lachmann J. 2017. Content of flavan-3-ol monomers and gallic acid in grape seeds by variety and year. *Vitis: J Grape Res*, 56: 45-48.
- Stanely Mainzen Prince P, Priscilla H, Devika PT. 2009. Gallic acid prevents lysosomal damage in isoproterenol induced cardiotoxicity in Wistar rats. *Eur J Pharmacol*, 615: 139-143.
- Priscilla DH, Prince PS. 2009. Cardioprotective effect of gallic acid on cardiac troponin-T, cardiac marker enzymes, lipid peroxidation products and antioxidants in experimentally induced myocardial infarction in Wistar rats. *Chem Biol Interact*, 179: 118-124.
- Qin W, Chung AC, Huang XR, Meng XM, Hui DS, Yu CM, Sung JJ, Lan HY. 2011. TGF- β /Smad3 signaling promotes renal fibrosis by inhibiting miR-29. *J Am Soc Nephrol*, 22: 1462-1474.
- Ramezani-Aliakbari F, Badavi M, Dianat M, Mard SA, Ahangarpour A. 2017. Effects of gallic acid on hemodynamic parameters and infarct size after ischemia-reperfusion in isolated rat hearts with alloxan-induced diabetes. *Biomed Pharmacother*, 96: 612-618.
- Rather SA, Saravanan N. 2013. Protective effect of gallic acid on immobilization induced stress in encephalon and myocardium of male albino Wistar rats. *Int J Nutr Pharmacol Neurol Dis*, 3:296-275.
- Rhoden E, Teloken C, Lucas M, Rhoden C, Mauri M, Zettler C, Bello-Klein A, Barros E. 2002. Protective effect of allopurinol in the renal ischemia-reperfusion in uninephrectomized rats. *Gen Pharmacol*, 35: 189-193.
- Rose BA, Force T, Wang Y. 2010. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. *Physiol Rev*, 90: 1507-1546.
- Ryu Y, Jin L, Kee HJ, Piao ZH, Cho JY, Kim GR, Choi SY, Lin MQ, Jeong MH. 2016. Gallic acid prevents isoproterenol-induced cardiac hypertrophy and fibrosis through

- regulation of JNK2 signaling and Smad3 binding activity. *Sci Rep*, 6: 34790.
- Sag CM, Santos CX, Shah AM. 2014. Redox regulation of cardiac hypertrophy. *J Mol Cell Cardiol*, 73: 103-111.
- Sanderson TH, Reynolds CA, Kumar R, Przyklenk K, Hüttemann M. 2013. Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. *Mol Neurobiol*, 47: 9-23.
- Sandoo A, van Zanten JJ, Metsios GS, Carroll D, Kitas GD. 2010. The endothelium and its role in regulating vascular tone. *Open Cardiovasc Med J*, 4: 302-312.
- Schirone L, Forte M, Palmerio S, Yee D, Nocella C, Angelini F, Pagano F, Schiavon S, Bordin A, Carrizzo A, Vecchione C, Valenti V, Chimenti I, De Falco E, Sciarretta S, Frati G. 2017. A review of the molecular mechanisms underlying the development and progression of cardiac remodeling. *Oxid Med Cell Longev*, 2017: 3920195.
- Segura AM, Frazier OH, Buja LM. 2014. Fibrosis and heart failure. *Heart Fail Rev*, 19: 173-185.
- Sen S, Asokkumar K, Umamaheswari M, Sivashanmugam AT, Subhadradevi V. 2013. Antiulcerogenic effect of gallic acid in rats and its effect on oxidant and antioxidant parameters in stomach tissue. *Indian J Pharm Sci*, 75: 149-155.
- Soong YY, Barlow PJ. 2006. Quantification of gallic acid and ellagic acid from longan (*Dimocarpus longan* Lour.) seed and mango (*Mangifera indica* L.) kernel and their effects on antioxidant activity. *Food Chem*, 97: 524-530.
- Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. 2014. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*, 63: 2889-2934.
- Suwalsky M, Colina J, Gallardo MJ, Jemiola-Rzeminska M, Strzalka K, Manrique-Moreno M, Sepúlveda B. 2016. Antioxidant capacity of gallic acid in vitro assayed on human erythrocytes. *J Membr Biol*, 249: 769-779.
- Umadevi S, Gopi V, Elangovan V. 2014. Regulatory mechanism of gallic acid against advanced glycation end products induced cardiac remodeling in experimental rats. *Chem Biol Interact*, 208: 28-36.
- Umadevi S, Gopi V, Simna SP, Parthasarathy A, Yousuf SM, Elangovan V. 2012. Studies on the cardio protective role of gallic acid against age-induced cell proliferation and oxidative stress in H9C2 (2-1) cells. *Cardiovasc Toxicol*, 12: 304-311.
- Verdecchia P, Angeli F, Gattobigio R, Guerrieri M, Benemio G, Porcellati C. 2004. Does the reduction in systolic blood pressure alone explain the regression of left ventricular hypertrophy? *J Hum Hypertens*, 18: S23-S28.
- Wang J, Chen H, Seth A, McCulloch CA. 2003. Mechanical force regulation of myofibroblast differentiation in cardiac fibroblasts. *Am J Physiol Heart Circ Physiol*, 285: H1871-H1881.
- Wang K, Zhu X, Zhang K, Zhu L, Zhou F. 2014. Investigation of gallic acid induced anticancer effect in human breast carcinoma mcf-7 cells. *J Biochem Mol Toxicol*, 28: 387-393.
- Zern TL, Fernandez ML. 2005. Cardioprotective effects of dietary polyphenols. *J Nutr*, 135: 2291-2294.
- Zhang HY, Wang LF. 2002. Theoretical elucidation on structure-antioxidant activity relationships for indolinonic hydroxylamines. *Bioorg Med Chem Lett*, 12: 225-227.
- Zhao G, Gao H, Qiu J, Lu W, Wei X. 2010. The molecular mechanism of protective effects of grape seed Proanthocyanidin extract on reperfusion arrhythmias in rats in vivo. *Biol Pharm Bull*, 33: 759-762.